openPR Logo
Press release

IDT offers a complete range of gene silencing products

06-01-2011 07:36 AM CET | Science & Education

Press release from: Integrated DNA Technologies

Pre-designed and customized products enable knockdowns in all cell types

Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, offers a comprehensive range of customizable products for RNA interference (RNAi) applications. The Screening Dicer-substrate siRNA (DsiRNA) provides researchers with a cost-effective and quick solution for their RNAi requirements. IDT’s DsiRNAs are chemically synthesised 27-mer RNA duplexes optimised for Dicer processing and incorporation into the RISC complex, resulting in an increase in potency. IDT’s Pre-designed library includes over 3,000,000 DsiRNAs designed against human, mouse, rat, cow, dog, chicken and chimp transcriptomes within RefSeq, enabling the production of DsiRNAs to meet the majority of user requirements.

When developing pre-designed DsiRNA duplexes, site selection is first performed using a proprietary algorithm with novel design rules. The sequences are subsequently screened to minimize the potential for cross-hybridisation and off-target effects, while sequences containing any known small nucleotide polymorphisms (SNPs) or alternatively spliced exons are eliminated. IDT therefore offers two variants of predesigned DsiRNA duplexes: splice common and splice specific. Splice common duplexes target all known variants of a gene in RefSeq and 8 – 10 duplexes are available for each target gene. Splice specific duplexes target exons present in particular splice variants, making them ideal for researchers targeting specific isoforms.

Further to the range of pre-designed products, IDT offers researchers custom DsiRNA, RNAi duplex oligos, custom RNAi design as well as antisense oligos. Produced on IDT’s proprietary high-throughput synthesis platform, the process has been designed to assure a high quality product at a low cost. Facilitating ease of use, custom orders can be placed via the user-friendly SciTools interface.

For more information on the complete range of IDT’s products please visit www.idtdna.com.

About IDT
Integrated DNA Technologies (IDT) is the largest supplier of custom nucleic acids in the United States, serving academic, government, and commercial researchers in biotechnology, clinical diagnostics, and pharmaceutical development. IDT's primary business is the manufacture of custom, synthetic DNA and RNA oligonucleotides. Today, IDT synthesizes and ships an average of 36,000 custom oligos per day to more than 86,000 customers worldwide. IDT manufacturing locations include facilities in Coralville, Iowa; San Diego, Calif.; and Leuven, Belgium. For more information visit www.idtdna.com.
Integrated DNA Technologies
800-328-2661 (US & Canada)
+1 319-626-8400 (outside US)
productinfo@idtdna.com
www.idtdna.com

Alto Marketing

Alto Marketing Limited| Office 3 Universal Marina | Crableck Lane | Sarisbury Green | Southampton | SO31 7AL

IDT enquiries Integrated DNA Technologies
Lynette Brown – Advertising and Product Manager
t: +1 319-665-7208 e: lbrown@idtdna.com

Media enquiries Alto Marketing Limited
Carolyn Butchers – Account Executive
t: +44 (0)1489 557672 e:carolynb@alto-marketing.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release IDT offers a complete range of gene silencing products here

News-ID: 177405 • Views:

More Releases from Integrated DNA Technologies

Troubleshooting and Optimizing Mutagenesis
Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, provides in-depth protocols and troubleshooting suggestions for your mutagenesis applications. As part of the new, free-to-download IDT Mutagenesis Applications Guide, an extensive troubleshooting section makes it possible to optimize your mutagenesis experiments for the best possible resulting data. Everything from primer design, reaction setup, ligation and transformation efficiency, to specific reaction components and PCR parameters, are covered. The guide provides
IDT DsiRNAs Used to Map Pain Pathways in the CNS
Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, distributes the highly informative newsletter, DECODED. In this quarter’s edition the work carried out by Dr Philippe Sarret and colleagues is discussed in detail. Sarret’s laboratory is based at the Université de Sherbrooke (Quebec, Canada), where researchers are investigating novel ways to develop analgesics and are the first to attempt RNA interference (RNAi) via direct in vivo targeting of genes
IDT’s newsletter provides an insight into the therapeutic use of RNAi
Decoded issue 2 – Featuring an interview with Dr John Rossi Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, has released the second issue of its educational and informative newsletter, Decoded. Available to download for free, the second issue of this quarterly newsletter includes a wealth of scientific content, and features an interview with Dr John Rossi (Department of Molecular and Cellular Biology and Beckman Research Institute of City
The IDT OligoCard for quick and simple ordering
Pre-payment card simplifies the oligonucleotide purchase process Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, makes it easy to purchase high quality oligonucleotides using its pre-pay OligoCard system. Credit can be easily transferred to an OligoCard using just a single PO or credit card transaction, minimizing paperwork. Oligos can then be ordered immediately, eliminating the delays associated with purchase authorization, maximizing efficiency. Transaction history is available online around the

All 5 Releases


More Releases for RNA

Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand. Browse 156 Market Data Tables and 112 Figures spread through 175
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited. Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and